FDA Panel Likes Janssen Diabetes Drug
(MedPage Today) -- After a day of deliberations, an FDA advisory committee concluded that the agency should approve Invokana (canagliflozin), a novel agent for type 2 diabetes.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana